Please login to the form below

Not currently logged in
Email:
Password:

Actavis mounts patent challenge on Velcade in US

Plans to launch own version of Takeda’s cancer drug

Takeda, Velcade

Generic drugmaker Actavis has filed a legal challenge against Takeda subsidiary Millennium Pharmaceuticals seeking to overturn its US patent protection on multiple myeloma and mantle cell lymphoma treatment Velcade.

Actavis' new parent company Watson Pharmaceuticals said the company had filed for approval of a generic product based on bortezomib, the active ingredient in Velcade, and had promptly been sued by Millennium for patent infringement.

Under US law, the lawsuit introduces an immediate 30-month stay on FDA approval of the generic unless Actavis can overturn patents protecting Velcade.

Millennium's defence of Velcade rests on two US patents (6,713,446 and 6,958,319) which were filed in 2005 and are both due to expire on January 5, 2022, according to court documents filed by the company.

Velcade is Millennium's biggest-selling product and had sales of around $740m in the 12 months ending October 31, 2012, according to IMS Health data.

The drug acts as a proteasome inhibitor and was first approved in the US in 2003 as an intravenous therapy and is now also available in a subcutaneous formulation.

Outside the US it is marketed by Johnson & Johnson, which said in November it recorded almost $1bn in sales for the product in the first nine months of 2012, a 16 per cent increase driven by approvals of the subcutaneous formulation in the EU and Canada.

2nd January 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Indigenus

A global healthcare communications network dedicated to helping clients grow their brands. Unstuck, with an entrepreneurial and nimble spirit....

Latest intelligence

Paywatch and the market access waters
Understanding and responding to payers’ needs has become priority number one for pharma as it battles the choppy seas of the global health economy...
EY Life Sciences Sector Update
Asia-Pacific and Japan...
A roadmap to strategic drug pricing
The current unit-based pricing model for drugs is too one-dimensional for the market's present needs. Pharma firms must identify products that will benefit from innovative pricing models, and then forge...

Infographics